{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:57:55Z","timestamp":1791352675870,"version":"4.3.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T00:00:00Z","timestamp":1453248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T00:00:00Z","timestamp":1453248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>ALK receptor tyrosine kinase has been shown to be a therapeutic target in neuroblastoma. Germline ALK activating mutations are responsible for the majority of hereditary neuroblastoma and somatic ALK activating mutations are also frequently observed in sporadic cases of advanced NB. Crizotinib, a first-line therapy in the treatment of advanced non-small cell lung cancer (NSCLC) harboring ALK rearrangements, demonstrates striking efficacy against ALK-rearranged NB. However, crizotinib fails to effectively inhibit the activity of ALK when activating mutations are present within its kinase domain, as with the F1174L mutation. Here we show that a new ALK inhibitor AZD3463 effectively suppressed the proliferation of NB cell lines with wild type ALK (WT) as well as ALK activating mutations (F1174L and D1091N) by blocking the ALK-mediated PI3K\/AKT\/mTOR pathway and ultimately induced apoptosis and autophagy. In addition, AZD3463 enhanced the cytotoxic effects of doxorubicin on NB cells. AZD3463 also exhibited significant therapeutic efficacy on the growth of the NB tumors with WT and F1174L activating mutation ALK in orthotopic xenograft mouse models. These results indicate that AZD3463 is a promising therapeutic agent in the treatment of NB.<\/jats:p>","DOI":"10.1038\/srep19423","type":"journal-article","created":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T07:11:43Z","timestamp":1453273903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis"],"prefix":"10.1038","volume":"6","author":[{"given":"Yongfeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia L.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi A.","family":"Muscal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,20]]},"reference":[{"key":"BFsrep19423_CR1","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"JM Maris","year":"2010","unstructured":"Maris, J. M. Recent advances in neuroblastoma. The New England journal of medicine 362, 2202- 2211 (2010).","journal-title":"The New England journal of medicine"},{"key":"BFsrep19423_CR2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrc3526","volume":"13","author":"NK Cheung","year":"2013","unstructured":"Cheung, N. K. & Dyer, M. A. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nature reviews. Cancer 13, 397\u2013411 (2013).","journal-title":"Nature reviews. Cancer"},{"key":"BFsrep19423_CR3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ccell.2015.02.005","volume":"27","author":"FH Wilson","year":"2015","unstructured":"Wilson, F. H. et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer cell 27, 397\u2013408 (2015).","journal-title":"Cancer cell"},{"key":"BFsrep19423_CR4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s10495-014-1066-0","volume":"20","author":"H Zhang","year":"2015","unstructured":"Zhang, H. et al. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis: an international journal on programmed cell death 20, 50\u201362 (2015).","journal-title":"Apoptosis: an international journal on programmed cell death"},{"key":"BFsrep19423_CR5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-0033-1357132","volume":"225","author":"JH Schulte","year":"2013","unstructured":"Schulte, J. H. et al. Targeted Therapy for Neuroblastoma: ALK Inhibitors. Klinische Padiatrie 225, 303\u2013308 (2013).","journal-title":"Klinische Padiatrie"},{"key":"BFsrep19423_CR6","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1158\/1078-0432.CCR-09-2660","volume":"16","author":"S De Brouwer","year":"2010","unstructured":"De Brouwer, S. et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clinical cancer research: an official journal of the American Association for Cancer Research 16, 4353\u20134362 (2010).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"BFsrep19423_CR7","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1200\/JCO.2009.27.0421","volume":"28","author":"MA Smith","year":"2010","unstructured":"Smith, M. A. et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 28, 2625\u20132634 (2010).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep19423_CR8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s10147-012-0417-5","volume":"17","author":"J Hara","year":"2012","unstructured":"Hara, J. Development of treatment strategies for advanced neuroblastoma. International journal of clinical oncology 17, 196\u2013203 (2012).","journal-title":"International journal of clinical oncology"},{"key":"BFsrep19423_CR9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nature07399","volume":"455","author":"Y Chen","year":"2008","unstructured":"Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971\u2013974 (2008).","journal-title":"Nature"},{"key":"BFsrep19423_CR10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature07397","volume":"455","author":"RE George","year":"2008","unstructured":"George, R. E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975\u2013978 (2008).","journal-title":"Nature"},{"key":"BFsrep19423_CR11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature07398","volume":"455","author":"I Janoueix-Lerosey","year":"2008","unstructured":"Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967\u2013970 (2008).","journal-title":"Nature"},{"key":"BFsrep19423_CR12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrclinonc.2012.72","volume":"9","author":"EL Carpenter","year":"2012","unstructured":"Carpenter, E. L. & Mosse, Y. P. Targeting ALK in neuroblastoma\u2013preclinical and clinical advancements. Nature reviews. Clinical oncology 9, 391\u2013399 (2012).","journal-title":"Nature reviews. Clinical oncology"},{"key":"BFsrep19423_CR13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ajpath.2011.12.003","volume":"180","author":"FA Duijkers","year":"2012","unstructured":"Duijkers, F. A. et al. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. The American journal of pathology 180, 1223\u20131231 (2012).","journal-title":"The American journal of pathology"},{"key":"BFsrep19423_CR14","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.1158\/0008-5472.CAN-08-4419","volume":"69","author":"L Passoni","year":"2009","unstructured":"Passoni, L. et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer research 69, 7338\u20137346 (2009).","journal-title":"Cancer research"},{"key":"BFsrep19423_CR15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nature07261","volume":"455","author":"YP Mosse","year":"2008","unstructured":"Mosse, Y. P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930\u2013935 (2008).","journal-title":"Nature"},{"key":"BFsrep19423_CR16","doi-asserted-by":"crossref","unstructured":"Hallberg, B. & Palmer, R. H. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nature reviews. Cancer 13 (2013).","DOI":"10.1038\/nrc3580"},{"key":"BFsrep19423_CR17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","volume":"26","author":"SC Bresler","year":"2014","unstructured":"Bresler, S. C. et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer cell 26, 682\u2013694 (2014).","journal-title":"Cancer cell"},{"key":"BFsrep19423_CR18","doi-asserted-by":"crossref","unstructured":"Bresler, S. C. et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Science translational medicine 3, 108ra114 (2011).","DOI":"10.1126\/scitranslmed.3002950"},{"key":"BFsrep19423_CR19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20101796","volume":"440","author":"C Schonherr","year":"2011","unstructured":"Schonherr, C. et al. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. The Biochemical journal 440, 405\u2013413 (2011).","journal-title":"The Biochemical journal"},{"key":"BFsrep19423_CR20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2012.06.001","volume":"22","author":"T Berry","year":"2012","unstructured":"Berry, T. et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer cell 22, 117\u2013130 (2012).","journal-title":"Cancer cell"},{"key":"BFsrep19423_CR21","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.18632\/oncotarget.1883","volume":"5","author":"A Cazes","year":"2014","unstructured":"Cazes, A. et al. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma. Oncotarget 5, 2688\u20132702 (2014).","journal-title":"Oncotarget"},{"key":"BFsrep19423_CR22","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","volume":"6","author":"JG Christensen","year":"2007","unstructured":"Christensen, J. G. et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Molecular cancer therapeutics 6, 3314\u20133322 (2007).","journal-title":"Molecular cancer therapeutics"},{"key":"BFsrep19423_CR23","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England journal of medicine 363, 1693\u20131703 (2010).","journal-title":"The New England journal of medicine"},{"key":"BFsrep19423_CR24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.semcancer.2011.09.005","volume":"21","author":"AM Azarova","year":"2011","unstructured":"Azarova, A. M., Gautam, G. & George, R. E. Emerging importance of ALK in neuroblastoma. Seminars in cancer biology 21, 267\u2013275 (2011).","journal-title":"Seminars in cancer biology"},{"key":"BFsrep19423_CR25","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-10-2956","volume":"70","author":"T Sasaki","year":"2010","unstructured":"Sasaki, T. et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer research 70, 10038\u201310043 (2010).","journal-title":"Cancer research"},{"key":"BFsrep19423_CR26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","volume":"14","author":"YP Mosse","year":"2013","unstructured":"Mosse, Y. P. et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study. The Lancet. Oncology 14, 472\u2013480 (2013).","journal-title":"The Lancet. Oncology"},{"key":"BFsrep19423_CR27","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","volume":"4","author":"L Friboulet","year":"2014","unstructured":"Friboulet, L. et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer discovery 4, 662\u2013673 (2014).","journal-title":"Cancer discovery"},{"key":"BFsrep19423_CR28","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1158\/0008-5472.CAN-14-3817","volume":"75","author":"ER Tucker","year":"2015","unstructured":"Tucker, E. R., Danielson, L. S., Innocenti, P. & Chesler, L. Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic. Cancer research 75, 2770\u20132774 (2015).","journal-title":"Cancer research"},{"key":"BFsrep19423_CR29","doi-asserted-by":"crossref","first-page":"e33581","DOI":"10.1371\/journal.pone.0033581","volume":"7","author":"P Mazot","year":"2012","unstructured":"Mazot, P. et al. Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment. PloS one 7, e33581 (2012).","journal-title":"PloS one"},{"key":"BFsrep19423_CR30","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2174\/18715206113139990130","volume":"13","author":"H Sun","year":"2013","unstructured":"Sun, H., Wang, Z. & Yakisich, J. S. Natural products targeting autophagy via the PI3K\/Akt\/mTOR pathway as anticancer agents. Anti-cancer agents in medicinal chemistry 13, 1048\u20131056 (2013).","journal-title":"Anti-cancer agents in medicinal chemistry"},{"key":"BFsrep19423_CR31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.actbio.2015.04.003","volume":"20","author":"FP Seib","year":"2015","unstructured":"Seib, F. P. et al. Focal therapy of neuroblastoma using silk films to deliver kinase and chemotherapeutic agents in vivo. Acta biomaterialia 20, 32\u201338 (2015).","journal-title":"Acta biomaterialia"},{"key":"BFsrep19423_CR32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbrc.2014.10.126","volume":"454","author":"F Xu","year":"2014","unstructured":"Xu, F., Li, H. & Sun, Y. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma. Biochemical and biophysical research communications 454, 566\u2013571 (2014).","journal-title":"Biochemical and biophysical research communications"},{"key":"BFsrep19423_CR33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bcp.2011.06.015","volume":"82","author":"A Notte","year":"2011","unstructured":"Notte, A., Leclere, L. & Michiels, C. Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochemical pharmacology 82, 427\u2013434 (2011).","journal-title":"Biochemical pharmacology"},{"key":"BFsrep19423_CR34","first-page":"934207","volume":"2015","author":"N Wang","year":"2015","unstructured":"Wang, N. & Feng, Y. Elaborating the role of natural products-induced autophagy in cancer treatment: achievements and artifacts in the state of the art. BioMed research international 2015, 934207 (2015).","journal-title":"BioMed research international"},{"key":"BFsrep19423_CR35","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3892\/ol.2015.3066","volume":"9","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Cordycepin induces apoptosis and autophagy in human neuroblastoma SK-N-SH and BE(2)-M17 cells. Oncology letters 9, 2541\u20132547 (2015).","journal-title":"Oncology letters"},{"key":"BFsrep19423_CR36","doi-asserted-by":"crossref","first-page":"e78958","DOI":"10.1371\/journal.pone.0078958","volume":"8","author":"N Mohan","year":"2013","unstructured":"Mohan, N., Chakrabarti, M., Banik, N. L. & Ray, S. K. Combination of LC3 shRNA plasmid transfection and genistein treatment inhibited autophagy and increased apoptosis in malignant neuroblastoma in cell culture and animal models. PloS one 8, e78958 (2013).","journal-title":"PloS one"},{"key":"BFsrep19423_CR37","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.4161\/auto.26094","volume":"9","author":"M Dodson","year":"2013","unstructured":"Dodson, M. et al. Inhibition of glycolysis attenuates 4-hydroxynonenal-dependent autophagy and exacerbates apoptosis in differentiated SH-SY5Y neuroblastoma cells. Autophagy 9, 1996\u20132008 (2013).","journal-title":"Autophagy"},{"key":"BFsrep19423_CR38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.toxlet.2013.08.015","volume":"223","author":"JH Park","year":"2013","unstructured":"Park, J. H. et al. Potential autophagy enhancers protect against fipronil-induced apoptosis in SH-SY5Y cells. Toxicology letters 223, 25\u201334 (2013).","journal-title":"Toxicology letters"},{"key":"BFsrep19423_CR39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.amjsurg.2013.01.008","volume":"205","author":"TC Krosch","year":"2013","unstructured":"Krosch, T. C. et al. Triptolide-mediated cell death in neuroblastoma occurs by both apoptosis and autophagy pathways and results in inhibition of nuclear factor-kappa B activity. American journal of surgery 205, 387\u2013396 (2013).","journal-title":"American journal of surgery"},{"key":"BFsrep19423_CR40","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3892\/ijo.2012.1678","volume":"42","author":"GS Sailaja","year":"2013","unstructured":"Sailaja, G. S. et al. The secreted protein acidic and rich in cysteine (SPARC) induces endoplasmic reticulum stress leading to autophagy-mediated apoptosis in neuroblastoma. International journal of oncology 42, 188\u2013196 (2013).","journal-title":"International journal of oncology"},{"key":"BFsrep19423_CR41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11010-012-1416-6","volume":"371","author":"G Rafatian","year":"2012","unstructured":"Rafatian, G., Khodagholi, F., Farimani, M. M., Abraki, S. B. & Gardaneh, M. Increase of autophagy and attenuation of apoptosis by Salvigenin promote survival of SH-SY5Y cells following treatment with H(2)O(2). Molecular and cellular biochemistry 371, 9\u201322 (2012).","journal-title":"Molecular and cellular biochemistry"},{"key":"BFsrep19423_CR42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.canlet.2011.11.036","volume":"318","author":"R Francisco","year":"2012","unstructured":"Francisco, R. et al. Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Cancer letters 318, 42\u201352 (2012).","journal-title":"Cancer letters"},{"key":"BFsrep19423_CR43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bcp.2010.03.031","volume":"80","author":"CR Archer","year":"2010","unstructured":"Archer, C. R. et al. Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt\/PKB activation in neuroblastoma. Biochemical pharmacology 80, 170\u2013178 (2010).","journal-title":"Biochemical pharmacology"},{"key":"BFsrep19423_CR44","doi-asserted-by":"crossref","first-page":"8737","DOI":"10.18632\/oncotarget.2372","volume":"5","author":"NF Moore","year":"2014","unstructured":"Moore, N. F. et al. Molecular rationale for the use of PI3K\/AKT\/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget 5, 8737\u20138749 (2014).","journal-title":"Oncotarget"},{"key":"BFsrep19423_CR45","doi-asserted-by":"crossref","first-page":"e1079","DOI":"10.1038\/cddis.2014.54","volume":"5","author":"J Cheng","year":"2014","unstructured":"Cheng, J. et al. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell death & disease 5, e1079 (2014).","journal-title":"Cell death & disease"},{"key":"BFsrep19423_CR46","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1158\/0008-5472.CAN-14-1169","volume":"74","author":"X Xu","year":"2014","unstructured":"Xu, X. et al. Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system. Cancer research 74, 6260\u20136270 (2014).","journal-title":"Cancer research"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep19423","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep19423.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep19423.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T17:46:29Z","timestamp":1672854389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep19423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,5,10]]}},"alternative-id":["BFsrep19423"],"URL":"https:\/\/doi.org\/10.1038\/srep19423","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,20]]},"assertion":[{"value":"28 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19423"}}